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Abstract
Background: The majority of patients with pancreatic cancer are non-resectable and jaundiced at
presentation. Methods of palliation in such patients with locally advanced disease comprise endoscopic
placement of a biliary endoprosthesis or surgical bypass.
Methods: This retrospective study compared morbidity, mortality, hospital stay, readmission rate and
survival in consecutive patients with incurable locally advanced pancreatic ductal adenocarcinoma.
Results: We identified a total of 56 patients, of whom 33 underwent endoscopic stenting and 23
underwent a surgical bypass consisting of a hepaticojejunostomy-en-Y and a gastrojejunostomy. There
were no significant differences in complication or mortality rates between patients undergoing palliative
stenting and those undergoing palliative surgery. However, after excluding admissions for chemotherapy-
related problems, the number of readmissions expressed as a percentage of the group population size
was greater in stented patients compared with biliary bypass patients (39.4% vs. 13.0%, respectively;
P < 0.05). Overall survival amongst patients undergoing palliative bypass was significantly greater than in
stented patients (382 days vs. 135 days, respectively; P < 0.05).
Conclusions: On analysis of these data and the published literature, we conclude that surgical bypass
represents an effective method of palliation for patients with locally advanced pancreatic cancer. Patients
need to be carefully selected with regard to both operative risk and perceived overall survival.
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Introduction
Up to 80% of ductal adenocarcinomas of the head of the pancreas
are not resectable at presentation.1,2 As 70–90% of patients with
carcinomas of the head of the pancreas and ampullary region
have jaundice at presentation,3–5 palliation that ensures biliary
drainage represents a large proportion of the hepatobiliary
surgeon’s workload.
Various therapeutic options have been described. Some centres
advocate resection surgery even in the palliative setting, arguing
that it may offer a survival advantage or better palliation and has
equivalent morbidity and mortality rates to bypass surgery,6–8 but
these results are disputed by other groups.9 Other options include
surgical biliary bypass incorporating either an hepatojejunostomy
(choledochojejunostomy),10–12 cholecystojejunostomy12,13 or cho-
ledochoduodenostomy10,12 with or without a concomitant gas-
trojejunostomy.14 More recently, these procedures have been
undertaken laparoscopically, with reportedly low morbidity and
mortality.15,16
In addition, biliary endoprostheses can be employed to
relieve biliary stasis. Internal drainage of the biliary tree via
the transhepatic route was first described in 1978.17,18
The introduction of endoscopically placed stents enabled the
use of larger-calibre endoprostheses.19,20 The advantage of
biliary stents is that their positioning is a minimally invasive
procedure which is well tolerated by patients. However, their
palliative potential is limited by the recurrence of jaundice
secondary to stent migration or accretion. Tumour progression
and duodenal invasion may render repeated stenting
impossible.
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The aim of this study was to compare morbidity and mortality
rates and effectiveness of palliation between patients matched
for tumour size and clinical stage who underwent surgical by-
pass or endoscopic stenting for locally advanced pancreatic
adenocarcinoma.
Materials and methods
Study methodology
Case notes were analysed retrospectively for all patients who pre-
sented consecutively to the University Hospitals of Leicester from
January 2003 to April 2004 with primary cancer of the head of the
pancreas, requiring palliation of their malignant obstructive jaun-
dice. Data were divided into two treatment groups consisting of,
respectively, patients who underwent stenting +/- chemotherapy
and patients who underwent palliative surgery +/- chemotherapy.
All patients with metastatic disease proven by radiological or sur-
gical assessment were excluded from the final analyses. Patients
with histological diagnoses other than adenocarcinoma were also
excluded.
Date of diagnosis was the first computed tomography (CT)
scan date. Tumour size was defined by surgical or radiological
staging. In patients for whom no histology was available, the diag-
nosis of pancreatic cancer was based on information from the
clinical history, radiology reports and tumour marker levels.
CA19.9 was considered significant if it was above the upper
normal limit of our local laboratories (>37 kU/l). Patients with
normal CA19.9 values were excluded from the final analyses.
Initial hospital stay duration was defined as the time spent in
hospital after the patient’s surgical or endoscopic procedure. Data
on short- and longterm morbidity in terms of postoperative com-
plications and hospital readmissions were collected. Perioperative
complications were defined as occurring within 30 days after stent
insertion or surgery. Thirty-day mortality for each type of treat-
ment was calculated. Longterm disease-specific survival data were
collected by telephoning the appropriate general practice surgery
or from hospital records. The selection of patients for palliative
surgery over endoscopic palliation was based on patient prefer-
ence and judged fitness for operative intervention.
Data were analysed using spssVersion 11.5 (SPSS Inc., Chicago,
IL, USA). Median survival was analysed by the log rank test and
represented by Kaplan–Meier graphs. Other continuous data of
normal distribution were analysed by descriptive analysis with
means compared by independent t-test. Categorical variables were
analysed using Fisher’s exact test. A P-value of <0.05 was consid-
ered statistically significant.
Endoscopic technique
Patients undergoing therapeutic stenting received a plastic
endoprosthesis using a side-viewing endoscope under fluoro-
scopic guidance. The stent position was confirmed by its anatomic
location, visualization of bile drainage and injection of contrast
into the stent following placement to ensure its position above the
bile duct stricture.
Surgical technique
All patients undergoing palliative surgery underwent a double
bypass comprising a hepatojejunostomy-en-Y and gastrojejunos-
tomy (Fig. 1).
Results
Within the study period, a total of 56 eligible patients were iden-
tified. Of these, 33 underwent endoscopic stenting and 23 under-
went palliative surgery. Follow-up ranged from 1 to 86 weeks.
Baseline demographic and haematological values are displayed in
Table 1. Patients undergoing palliative surgery had significantly
lower CA19.9, despite having equivalent tumour sizes. No other
values differed statistically between the groups.
There were no significant differences in immediate complica-
tion or mortality rates between patients who underwent palliative
stenting and those who underwent palliative surgery (Table 2). In
the surgical group, the one death was attributed to respiratory
infection complicated by multiple organ failure. In the stent
group, causes of death were cholangitis (n = 1), acute renal failure
(n = 2), upper gastrointestinal haemorrhage (n = 1) and respira-
tory complications (n = 2). After excluding admissions for
chemotherapy-related problems (diarrhoea, skin rashes, anaemia
or vomiting occurring within 48 hours of treatment) the number
of readmissions expressed as a percentage of the group population
size was greater in stented patients compared with biliary bypass
surgery patients (39.4% vs. 13.0%, respectively) (Fig. 2). The total
length of stay in hospital per patient was also lower in the surgical
bypass group, even including their postoperative stay (34.1 days
vs. 10.2 days). The main reasons for readmission were jaundice
Figure 1 Surgical bypass procedure, final reconstruction
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and sepsis, which accounted for 76.9% of all readmissions. Two
patients in the endoscopic stent group developed intractable vom-
iting, which persisted despite discontinuing their chemotherapy,
and had radiological evidence of gastric outlet obstruction.
Neither individual proceeded to intervention as they quickly suc-
cumbed from advanced disease.
Overall survival amongst patients undergoing palliative bypass
was significantly greater than in stented patients at 382 days vs.
135 days, respectively (Fig. 3). Preoperative CA19.9 also appeared
to influence survival: in both groups, patients with CA19.9 values
<1000 survived significantly longer than those with CA19.9 >1000
(Fig. 4).
Discussion
Overall, these results suggest that surgical bypass can be per-
formed with equivalent morbidity and mortality rates to biliary
stenting in selected patients, but with a significantly lower risk of
readmission. Hence, better palliation can be achieved in patients
who are able to tolerate biliary bypass surgery. However, quality of
life data are needed to add further strength to this observation.
The increased survival observed in the surgical bypass cohort is
probably the result of a better overall state of fitness, reflected in
the lower median age of patients undergoing surgery. In addition,
patients who underwent bypass surgery had significantly lower
CA19.9 levels than those who underwent endoscopic stenting
(Table 1). In this study, we found CA19.9 levels >1000 to be asso-
ciated with significantly lower survival than levels <1000 (Fig. 4).
Hence, despite our attempts to match patients using radiological
imaging, it is possible that patients who underwent endoscopic
Table 1 Demographic variables among patients undergoing endoscopic stenting and palliative surgery
Variable Palliative surgery group
(n = 23)
Endoscopic stent group
(n = 33)
Significance
Gender
Male 57% 49% NS
Female 43% 51%
Median age, years 65.2 69.0 NS
Median CA19.9, kU/l 1153.00 3878.50 <0.05
Median bilirubin, kU/l 189 290 NS
Median white cell count, ¥109/l 8.00 8.00 NS
Median C-reactive protein, mg/l 19.00 31.50 NS
Median tumour size, mm 30.00 32.50 NS
NS, not significant
Table 2 Hospital stay, complications and mortality within 30 days after palliative surgery or endoscopic stenting
Variable Palliative surgery group
(n = 23)
Endoscopic stent group
(n = 33)
P-value
Complications Sepsis 10 7 NS
43.5% 21.2%
Bleeding 8 5 NS
34.9% 15.1%
Stent blockage NA 2 NA
6.1%
30-day mortality 1 6 NS
4.3% 18.1%
NS, not significant; NA, not applicable
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stenting had a higher occult tumour burden than those who
underwent bypass surgery, which would doubtless have negatively
impacted on their longterm survival.
The survival of patients who underwent bypass may also be
influenced by our unit’s relatively conservative policy regarding
the selection of patients for pancreatic adenocarcinoma resec-
tion21 and the fact that no patients with distant pancreatic
metastases were included in the study. Despite these consider-
ations, it is conceivable that by avoiding recurrent admissions for
jaundice and concurrent sepsis, surgical bypass may contribute to
the increased survival in this group.
There are relatively few data examining the relative merits of
surgical bypass vs. endoscopic stenting in the literature: we found
only three randomized trials and a number of largely retrospective
studies, which are summarized in Table 3.22–33 In a review of the
randomized trials, Schwarz et al. concluded that an endoprosthe-
sis should be placed if there was evidence of hepatic, peritoneal
or pulmonary metastases or if the patient had significant
co-morbidity precluding surgery.34 However, it is worth noting
that a later meta-analysis noted that the evidence did not allow for
a definitive conclusion on which treatment was preferable.35
Despite this, the overall pattern would appear to indicate that, for
the most part, surgical bypass can be performed with similar
morbidity and mortality rates to endoprosthesis, but with a longer
initial hospital stay. Rates of late complications and readmissions
are greater in patients who undergo biliary stenting than in those
who undergo biliary bypass.
These published data would suggest that biliary endoprosthesis
should be reserved for those with a shorter expected survival and
that surgical palliation should be offered to those patients who are
expected to live longer and who are able to tolerate surgical inter-
vention. The cut-off in survival determining these two treatment
modalities has often been quoted at 6 months.22,23,25,29,34,36 Outwith
anaesthetic considerations, tumour-related determinants of poor
survival in the palliation of pancreatic cancer include C-reactive
protein levels,37 leucocytosis,37 duodenal invasion,38 liver
metastases,38 peritoneal dissemination,38 high bilirubin,39 low hae-
moglobin,39 low albumin,39 presence of ascites40 and the Karnofsky
index of performance status.41 These considerations are useful
when selecting cases appropriate for bypass procedures vs. endo-
scopic stenting.
During surgery, it is our policy to perform a gastrojejunostomy
at the time of a biliary bypass. It is probably worth noting that one
patient who underwent endoscopic palliation of a biliary obstruc-
tion re-presented with gastric outlet obstruction. The use of a
routine gastrojejunostomy is in keeping with current literature
showing that gastrojejunostomies can be performed with no
increase in morbidity and mortality and recommending that a
gastrojejunostomy and biliary bypass be undertaken as a single
procedure.14,36,42–46 The fact that two patients in the endoscopic
stent group in the present study developed gastric outlet obstruc-
tion also supports the use of prophylactic gastrojejunostomy in
patients undergoing operative intervention. It has been reported
that patients with liver metastases and carcinomatosis do not
survive long enough to develop gastric outlet obstruction;10
however, these patients would make poor surgical candidates and
are best treated using endoscopic means.
It remains to be seen what impact metallic stents will have on
surgical bypass procedures. Although they are more expensive
than conventional stents, metallic stents are purported to have
longer patency, but may still become occluded by tumour
ingrowth or overgrowth.47 Only one study, to date, has compared
surgical bypass with metallic stents; it concluded that metallic
stents were cost-effective when compared with surgical bypass but
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had a higher rate of late complications.25 The use of self-
expanding metal stents to treat malignant gastroduodenal outlet
obstruction raises the possibility of using endoscopic stents solely
to palliate advanced pancreatic cancer without the need for
bypass,48,49 although it would appear that even these gastrointes-
tinal stents are susceptible to tumour ingrowth.50 More data are
needed to evaluate this further.
Major limitations of this study refer to its retrospective nature
and small sample size. In conclusion, we tentatively suggest that,
based on evidence from our own data and the published literature,
the surgical double bypass is an efficacious means of palliating
patients with locally advanced pancreatic adenocarcinoma. The
published literature suggests that surgical bypass offers a lower
rate of late complications, but involves a higher rate of initial
complications and a longer hospital stay than stenting. By con-
trast, we have shown that surgical bypass can be performed with
equivalent morbidity and mortality rates and length of initial
hospital stay as endoscopic stenting, and that it results in a lower
rate of late complications. Surgical bypass in this series is associ-
ated with prolonged survival compared with palliative stenting.
Although the precise reasons for this remain unclear, it should
be an important consideration when considering palliation for
patients with pancreatic cancer.
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